CTLA4 and non-small cell lung carcinoma: Already approved Ipilimumab, a fully humanized anti-CTLA-4 mAb that targets protein receptors at the DC surface (44) is in a phase II trial as a first-line treatment of metastatic NSCLC, in association with chemotherapy.